Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Encoded Therapeutics launches with $104 million

by Ryan Cross
June 29, 2019 | A version of this story appeared in Volume 97, Issue 26

 

The gene-therapy start-up Encoded Therapeutics has emerged from stealth mode after raising $104 million in series C financing. The company’s lead program is for a type of epilepsy called Dravet syndrome, caused by a deficiency in a sodium channel. The sodium channel gene is too large to be delivered via viral gene therapy, so Encoded scientists devised a creative fix: they made a synthetic transcription factor that boosts expression of the gene, which itself is delivered with gene therapy. They’ve successfully tested the concept in mice and monkeys.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.